Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterNo recent work listed

Aaron Tyler Wild

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5008839368. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2012: 2 papers · 2013: 10 papers · 2014: 1 paper · 2015: 2 papers · 2016: 2 papers

Papers 17

  1. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.11.026↗
  2. Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management. Co-author DOI 10.1097/sla.0000000000001156↗
  3. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocar… Co-author DOI 10.1002/cncr.29161↗
  4. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1097/coc.0b013e3182940ff9↗
  5. Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer. Co-author DOI 10.6004/jnccn.2014.0006↗
  6. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relat… Co-author DOI 10.1007/s13566-013-0115-6↗
  7. Management of pancreatic cancer. Co-author DOI 10.1016/j.currproblcancer.2013.10.001↗
  8. Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents. Co-author DOI 10.1016/j.currproblcancer.2013.10.008↗
  9. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2013.03.032↗
  10. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic… Co-author DOI 10.1016/j.ijrobp.2013.06.2039↗
  11. Stereotactic body radiation therapy planning with duodenal sparing using volumetric-modulated arc therapy vs intensity-modulated radiation therapy in locally a… First author DOI 10.1016/j.meddos.2013.02.003↗
  12. A Phase 2 Multi-institutional Study to Evaluate Gemcitabine and Fractionated Stereotactic Radiotherapy for Unresectable, Locally Advanced Pancreatic Adenocarci… Co-author DOI 10.1016/j.prro.2013.01.016↗
  13. Understanding the Role of 18Flurodeoxyglucose PET in Predicting Improved Survival in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.prro.2013.01.090↗
  14. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. First author DOI 10.1200/jco.2012.44.7516↗
  15. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality ther… Co-author DOI 10.3978/j.issn.2078-6891.2013.044↗
  16. Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.1016/j.gie.2012.07.006↗
  17. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: impli… First author DOI 10.1016/j.radonc.2012.07.004↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Joseph M. Herman · 17 shared papers, 2012–2016 · strength 0.61
  2. Daniel A. Laheru · 13 shared papers, 2012–2016 · strength 0.44
  3. Christopher Lee Wolfgang · 12 shared papers, 2012–2016 · strength 0.40
  4. Timothy Michael Pawlik · 10 shared papers, 2012–2016 · strength 0.31
  5. Phuoc Tho Tran · 7 shared papers, 2013–2016 · strength 0.25
  6. Amy Hacker‐Prietz · 7 shared papers, 2012–2016 · strength 0.23
  7. Avani Satish Dholakia · 6 shared papers, 2013–2016 · strength 0.23
  8. Lei Zheng · 6 shared papers, 2013–2015 · strength 0.20
  9. Ralph H. Hruban · 6 shared papers, 2012–2016 · strength 0.19
  10. Katherine Y. Fan · 4 shared papers, 2013–2014 · strength 0.15
  11. Susannah G. Ellsworth · 4 shared papers, 2013–2016 · strength 0.14
  12. Christine A. Iacobuzio–Donahue · 4 shared papers, 2013–2016 · strength 0.14
  13. Rachit Kumar · 4 shared papers, 2012–2014 · strength 0.12
  14. Dung Thi Le · 4 shared papers, 2013–2014 · strength 0.12
  15. Barish H. Edil · 4 shared papers, 2012–2013 · strength 0.11
  16. Richard David Schulick · 4 shared papers, 2012–2013 · strength 0.11
  17. Eun Ji Shin · 3 shared papers, 2012–2016 · strength 0.10
  18. Mouen A. Khashab · 3 shared papers, 2012–2016 · strength 0.10
  19. Albert C. Koong · 3 shared papers, 2013–2015 · strength 0.10
  20. Daniel Tandel Chang · 3 shared papers, 2013–2015 · strength 0.10
  21. Siva P. Raman · 3 shared papers, 2013–2015 · strength 0.10
  22. Matthew John Weiss · 2 shared papers, 2016 · strength 0.09
  23. Ana De Jesus‐Acosta · 3 shared papers, 2013–2014 · strength 0.09
  24. Elliot K. Fishman · 3 shared papers, 2012–2014 · strength 0.09
  25. Ross C. Donehower · 3 shared papers, 2013 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.